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Abstract: As genome-wide association studies (GWAS) have grown in size, the number of genetic 
variants that have been associated per disease has correspondingly increased. Despite this increase 
in the number of single-nucleotide polymorphisms (SNPs) identified per disease, their biological 
interpretation has in many cases remained elusive. To address this, we have combined GWAS 
results with orthogonal sources of evidence, namely the current knowledge of molecular pathways; 
real-world clinical data from six million patients; RNA expression across tissues from Alzheimer’s 
disease (AD) patients, and purpose-built rodent models for experimental validation. In more detail, 
first we show that when examined at a pathway level, analysis of all GWAS studies groups AD in a 
cluster with disorders of immunity and inflammation. Using clinical data, we show that the degree 
of comorbidity of these diseases with AD correlates with the strength of their genetic association 
with molecular participants in the Janus kinases/signal transducer and activator of transcription 
(JAK-STAT) pathway. Using four independent RNA expression datasets we then find evidence for 
the altered regulation of JAK-STAT pathway genes in AD. Finally, we use both in vitro and in vivo 
rodent models to demonstrate that Aβ induces gene expression of the key drivers of this pathway, 
providing experimental evidence to validate these data-driven observations. These results therefore 
nominate JAK-STAT anomalies as a prominent aetiopathological event in AD and hence a potential 
target for therapeutic development, and moreover demonstrate a de novo multi-modal approach to 
derive information from rapidly increasing genomic datasets. 
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1. Introduction 
As genome wide association studies (GWAS) have grown in size, often now numbering tens of 
thousands of research participants, the number of genes identified as contributing to disease 
susceptibility have correspondingly grown. This is as true for Alzheimer’s Disease (AD) as it is for 
many other disorders, and bioinformatic and pathway analyses of this large number of susceptibility 
genes is providing a highly efficient method of proposing and prioritising underlying biological 
pathways for further study [1,2]. In some cases, this understanding adds to existing observations–
such as the evidence from GWAS that pathways of inflammation are important in AD–whereas in 
other cases pathway analysis yields less expected findings, such as evidence that cholesterol synthesis 
and endocytic recycling are part of the pathological process [3]. However, such analyses have their 
limitations due to our incomplete understanding of the canonical molecular pathways. Namely, 
many pathways described as categorical entities through data sources such as Kyoto Encyclopedia of 
Genes and Genomes (KEGG) and similar repositories, are skeletal at best and only contain a fraction 
of the genes that might be involved in any given process. Furthermore, many genes are nominated 
in multiple different pathways through their pleiotropic function. As an example, one of the most 
replicated associations with AD, the gene CLU encoding clusterin, is involved in processes as diverse 
as complement signaling, protein binding and chaperoning, and cell survival [4]. In the context of 
this incomplete understanding together with inherent molecular pathway complexity, determining 
the underlying biology of disease from GWAS studies alone becomes difficult and hence inevitably 
limited.  
In an effort to address this limitation, we reasoned that it should be possible to hone pathway 
analysis by utilising orthogonal datasets. Specifically, we hypothesised that pathways are more 
relevant to disease aetiopathogenesis if diseases that shared pathways also shared morbidity. Put 
another way, if two or more diseases are more commonly found to co-occur rather than by chance, 
and if those comorbid diseases also share molecular pathways, one would predict that those shared 
pathways are more likely to play a role in aetiopathogenesis. In order to test this reasoning, we 
combined pathway analysis of the GWAS associations from all diseases (as reported in the GWAS 
catalog; https://www.ebi.ac.uk/gwas/) together with a co-morbidity study from real-world data to 
identify shared pathological processes. We then tested the resulting pathway in observational and 
empirically derived genome wide expression datasets from human and rodent studies, and finally 
validated the results in empirical studies in rat models in vitro and in vivo. The results, demonstrating 
a role for JAK-STAT signaling in AD, are in line with the known contribution of inflammatory 
processes to the disease, but they further nominate a specific target for therapy and provide a possible 
approach to interpretation of GWAS data for other disease areas.  
2. Materials and Methods 
2.1. Overlap of Susceptibility Genes Across Human Disease 
In order to identify biological pathways shared across different diseases, we utilised the GWAS 
catalogue [5] to obtain a list of all known gene associations with disease derived from GWAS studies. 
We used the experimental factor ontology (EFO) [6] to identify disease studies, filtering by diseases 
with at least 25 associated genes, and only including the 25 strongest associated genes ranked by p 
value where more than 25 genes have been found to show some association. No other filters, such as 
date of study, were applied. For any two genes ‘α’and ‘β’sampled in the GWAS-catalogue, we then 
calculated the number of KEGG pathways that these two genes share, obtaining a gene × gene matrix 
of which we show a section in Figure 1. In order to determine whether the susceptibility genes of any 
given disease share more pathways with the susceptibility genes of any other given disease than 
expected from chance alone, we used a non-parametric Wilcoxon rank-sum test.  
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Figure 1. Number of shared pathways. Number of pathways shared by the top five genes of three of 
the studied diseases, namely Crohn’s Disease and Type 1 and Type 2 Diabetes mellitus. For any two 
genes (as indicated on the X and Y axes), the color of the corresponding cell represents how many 
KEGG pathways these two genes share. Each one of these 15 genes has been associated through a 
GWAS study with at least one of these diseases. Although performed for each disease in the GWAS 
Catalogue using the 20 most strongly associated genes (i.e., lowest p value), this figure only shows 
the top five genes and only three diseases for representational purposes. 
Formally, if we denote the gene × gene matrix as ‘n(α,β)’ (with ‘α’ and ‘β’ being any gene 
sampled in the GWAS-catalogue), ‘A’ as the set of genes associated with disease ‘A’, and ‘B’ as the 
set of genes associated with disease ‘B’, the first sample ‘S+’ of our test becomes: 
𝑆ା = {𝑛(𝛼, 𝛽)  𝑤𝑖𝑡ℎ  𝛼 ∈ 𝐴 & 𝛽 ∈ 𝐵} (1) 
while the second sample ‘S-’ becomes:  
𝑆ି = {𝑛(𝛼, 𝛽)  𝑤𝑖𝑡ℎ  (𝛼 ∉ 𝐴 & 𝛽 ∈ 𝐵)  𝑜𝑟  (𝛼 ∈ 𝐴 & 𝛽 ∉ 𝐵)} (2) 
then, a one-tailed Wilcoxon rank-sum test compares ‘S+’ against sample ‘S-’. The statistical results of 
this comparison determine whether diseases ‘A’ and ‘B’ share more pathways than expected from 
chance according to their GWAS associations. 
2.2. Contribution of Biological Pathways to Diseases 
Given that the results from the analysis described above suggested an intersection between AD 
and inflammatory diseases and hence confirming known associations, as discussed in the results and 
discussion sections, we subsequently focused on this overlap. For each inflammatory disease 
sampled in the GWAS-catalogue that had statistical power for subsequent analysis (see below), we 
calculated a so-called pathway load for each KEGG pathway. This is a numeric value that represents 
the proportion of susceptibility genes that a given disease has on a given KEGG pathway. Given 
disease ‘A’ and pathway ‘p’, the pathway load is equal to the number of susceptibility genes that 
disease ‘A’ has on pathway ‘p’, divided by the total number of times that any associated gene of 
disease ‘A’ is annotated as belonging to any KEGG pathway.  
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Formally, if we denote ‘m(A,p)’as the number of genes of disease ‘A’ that belong to pathway ‘p’, 
the pathway load is:  
𝑙𝑜𝑎𝑑(𝐴, 𝑝) = 𝑚(𝐴, 𝜌)∑ 𝑚(𝐴, 𝜌)∀ఘ
 (3) 
We divide by ∑ 𝑚(𝐴, 𝜌)∀ఘ  to control for diseases whose genes may have been more thoroughly 
studied, and therefore included in more KEGG pathways, than less studied diseases. 
2.3. Shared Contribution of Biological Pathways to Disease Comorbidity with AD 
We determine the comorbidity of inflammatory diseases with AD using the US National 
Hospital Discharge Survey (NHDS https://www.cdc.gov/nchs/nhds/, [7]) records from 1979 to 2006, 
which can be found in the Inter-university Consortium for Political and Social Research (ICPSR), file 
ICPSR 24281 (http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/24281), or in the National 
Archive of Computerized Data on Aging (NACDA [8]). This randomised survey collects medical 
information, including final diagnosis coded in ICD-9-CM and demographic data, from the discharge 
records of a number of hospitals in the US, totaling 6,552,504 patient discharges in the sample used 
here. The record only includes hospitals with an average patient stay length of 30 days or less, 
excluding military and hospitals from institutions such as prisons [7]. This is an epidemiological 
resource that observationally collects diagnosis and demographics of patients, and must not be 
mistaken with other bioinformatics resources that curate information on pathways of mechanisms, 
such as KEGG or Reactome. In NHDS we identified all patients in the dataset with a diagnosis of AD 
(ICD-9-CM code 331.0) and aged above 60 years in order to focus on late onset AD cases. For each 
case we find one control matched in gender, age, race and survey year (i.e., the year at which the 
survey was ran on that patient). To eliminate the diagnoses with the lowest statistical power, we 
analyse only the inflammatory diseases that had more than 15 patients among the AD cases and their 
matched controls. For each inflammatory disease, we calculate the number of patients of that disease 
in the AD population divided by the number of patients of that disease in the matched population. 
For descriptive purposes we call this value ratioAD(A). Finally, for each KEGG pathway, we calculate 
whether the pathway load (load(A,p)) values correlate with the AD ratios (ratioAD(A)) using 
Pearson’s correlation. 
2.4. Pathway Gene Expression Dysregulation in AD 
In order to examine the relationship between gene expression and disease we obtained RNA 
expression data from four independent datasets; 1) AddNeuroMed (ANM), a longitudinal multi-
centre cohort study with blood samples from 105 AD cases, 125 Mild Cognitive Impairment (MCI) 
individuals and 114 controls [9,10]; 2) the Dementia Case Register (DCR), a single centre longitudinal 
cohort utilising the exact same protocol as ANM with blood samples from 90 AD cases, 65 MCI 
individuals and 73 controls; 3) the largest post-mortem AD dataset available in ArrayExpress, E-
GEOD-44770, with samples of post-mortem pre-frontal cortex from 129 AD cases and 101 controls 
[11]; 4) a rodent in-vitro dataset of neuronal gene response to amyloid peptide [12]. Throughout this 
paper, these datasets are respectively denoted “Dataset 1”, “Dataset 2”, “Dataset 3” and “Dataset 4”. 
The case ascertainment, diagnostic process and other details of ANM have been described previously 
[9,10,13] while DCR used an identical clinical and laboratory protocol. Demographics from the three 
human cohorts (Datasets 1 to 3) are reported in Table 1.  
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Table 1. Characteristics of human datasets. 
 Dataset 1 (blood, ANM) 
Dataset 2 
(blood, DCR) 
Dataset 3 
(brain, AE) 
Species    
Homo Sapiens 344 228 229 
Gender (n)    
Female 209 148 108 
Male 135 80 121 
Age (years)    
mean ± SD 75.9 ± 6.8 78.1 ± 7.0 73.8 ± 12 
Centre (n)    
1 44 44 229 
2 34 11 - 
3 84 62 - 
4 43 43 - 
5 45 25 - 
6 94 43 - 
Diagnosis (n)    
AD 105 90 129 
control 114 73 100 
MCI 125 65 0 
Human study cohorts with the variables used in the linear model (ANM-AddNeuroMed; DCR-
dementia case register; AE-ArrayExpress–see methods for details). 
To test for statistically significant differences in RNA-expression in these four datasets for a 
given pathway, we use a per gene general linear model (GLM) with a binomial link function, which 
models AD status (two levels per person–either AD patient or control) as a function of RNA-
expression while controlling for a number of covariates (gender, age and sampling centre). The p 
values we report correspond to the RNA-expression variable per gene.  
2.5. Proof of Concept in an In Vitro Rat Model of Aβ Exposure 
In order to explore JAK-STAT signaling in vitro, primary neuronal cultures were generated from 
Sprague Dawley E18 rat embryos by papain dissociation according to the manufacturer’s instructions 
(Worthington, Lakewood, NJ, USA) and cultured as previously described [14]. Briefly, brains were 
harvested and maintained in sterile PBS, hippocampi and cortices were dissected out using a 
dissection microscope (MoticEurope, Barcelona, Spain), triturated using a sterile glass Pasteur pipette 
and maintained in serum-free medium. Viable cells were counted using a hemacytometer 
(ThermoFisher Scientific, Waltham, MA, USA). Neurons were plated in Neurobasal medium 
supplemented with B27, 0.30% glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin, at a 
density of 300,000 cells/mL in plates coated with poly-D-lysine and incubated at 37 °C in 5% CO2 
atmosphere. Neuronal cultures were treated 7–9 days post-plating.  
Aβ1–42 peptide was purchased from Dr. David Teplow (California, UCLA) and was 
resuspended in 100% 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP) at a final concentration of 1 mM. For 
complete solubilisation the peptide was homogenized using a Teflon plugged 250 μL Hamilton 
syringe. HFIP was removed by evaporation in a SpeedVac (Fisher Scientific UK Ltd. Loughborough, 
Leicestershire, UK), Aβ1–42 resuspended at a concentration of 5 mM in dimethylsulfoxide (DMSO) 
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and sonicated for 10 min. Oligomers were prepared as previously described [15]: Aβ1–42 was diluted 
in PBS to 400 μM and 1/10 volume 2% sodium dodecyl sulfate (SDS) in H2O added. Aβ was incubated 
for 24 h at 37 °C and further diluted to 100 μM in PBS followed by 18 h incubation at 37 °C. Rat 
primary neuronal cultures were treated with 3 μM Aβ for either 4 h or 24 h. These time points were 
selected based on the commonly observed time progression of changes in RNA after Aβ treatment. 
2.6. Proof of Concept in an In Vivo Rat Model of Aβ Exposure 
We further tested whether the observations made in vitro were also found in in vivo models. 
Male wild type Wistar rats (approximately 300g body weight, 8 weeks of age) were subjected to 
bilateral injections of 50 μM Aβ1-42 or PBS (n = 5 per group) into the lateral ventricles (QPS, 
Grambach, Austria). Brains were collected 3 h post injection. Entorhinal cortex was subdissected, 
frozen in liquid nitrogen and processed for RNA extraction. Frozen tissues were thawed and 
homogenised in Trizol and total RNA extracted according to the manufacturer’s instructions 
(Invitrogen, Paisley, UK).  
Total RNA from entorhinal cortex (1 μg) was reverse transcribed using random hexamers and a 
Taqman RT kit (Applied Biosystems, Cheshire, UK) according to the manufacturer’s instructions. 
PCR primers were designed using the Universal Probe Library package (Roche Molecular 
Biochemicals, Lewes, UK) and used in SYBR Green-based PCR reactions performed on a 
StepOnePlusTM (96 well) thermal cycler (Applied Biosystems, California, USA). Relative 
quantification of gene expression between samples was determined using the 2−ΔΔCT method as 
described by Livak and Schmittgen [16]. Internal control genes used to normalise for RNA input were 
HPRT and β-actin.  
Primer sequences: Jak1(NM_053466.1): Forward: 5′-ccaccgggacatttcact-3’; Reverse: 5´-
ttgtgggaaacctgtctcatc-3´; Jak2 (NM_031514.1): Forward: 5´-ggagagtatgttgccgaagaa-3´ ; Reverse: 3´-
atattatgatacacaggcgtaatacca-3´; Jak3 (NM_012855.2): Forward: 5´-ggccaaagtcccatcttct-3´; Reverse: 5´-
gaagctccacacgtcagattg-3´; Tyk2 (Non-receptor tyrosine-protein kinase, NM_001257347.1): Forward: 
5´-tgccatcttgctctcaacc-3´; Reverse: 5´-gtgagggatacagttcttgaagc-3´. 
All samples were run in triplicate from three independent experiments. The mean crossing 
threshold (CT) values for both the target and internal control genes in each sample were determined 
and the 2−ΔΔCT calculations performed. The fold change in the target genes (after normalising to the 
internal control gene) were calculated for each sample and the mean calculated. Statistical 
significance was determined by Student´s t-test. Data are represented as normalised fold increases 
over control samples. Values are given as mean ± s.e.m (standard error of the mean). 
2.7. Ethical Considerations 
All animal studies described in this manuscript were ethically reviewed and carried out in 
accordance with Animals (Scientific Procedures) Act 1986. We further certify that the research 
(including Embryonic and Fetal Research if appropriate) was conducted according to the 
requirements of POL-GSKF-410 and associated relevant SOPs, and that all related documentation is 
stored in an approved HBSM database. Human biological samples were sourced ethically and their 
research use was in accord with the terms of the informed consents 
3. Results  
3.1. Genes Associated with AD Show Shared Susceptibility to Diseases of Immunity 
Given that recent large scale association studies suggest genes related to AD risk are involved in 
many different biological pathways, only some of which would have been predicted in advance, we 
wondered whether some of these pathway associations would be shared with other diseases. To 
address this question systematically, we first obtained from the GWAS catalogue [5] a list of all genes 
that have been found to be associated with all diseases in that dataset. Subsequently, for each gene 
appearing in the list, we determined the number of KEGG pathways that that gene shared with each 
other gene on the list. As a general concept, we assume at this point that if two genes, one associated 
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with one disorder and the other associated with a second disorder, both appear in the same biological 
pathways, then those pathways should commonly be associated with both diseases.  
Using this data of genes associated with diseases and the KEGG pathways that those genes 
appear in, we then generated a gene-gene matrix, plotting for each gene associated with each disease 
the numbers of KEGG pathways shared with genes associated with each other disease in the dataset. 
Not surprisingly, we find many genes participate in many different pathways. This is illustrated for 
three disorders in Figure 1, using for this explanatory purpose five genes only. In this illustrative 
segment of the data, it can be seen that the genes associated with Crohn’s disease in particular 
participate in many different named KEGG pathways. Again, this is unsurprising as these genes are 
part of the human leukocyte antigen system encoding the major histocompatability complex; a much-
studied master regulator of immunity. Using this gene-gene matrix we are then able to explore which 
diseases share pathways with other diseases. Again, in the illustrative segment of the data in Figure 
1 it can be seen that the genes associated with Crohn’s disease share no pathways with the genes 
associated with Type 2 diabetes (T2DM) but do share considerable numbers of KEGG pathways with 
genes associated with Type 1 diabetes (T1DM). Note that this observation is not driven by the same 
genes being associated with any two diseases, as we exclude from the comparison the number of 
pathways that HLA-DRB1 shares with itself in the T1DM-Crohn’s instance. Rather the T1DM-
Chrohn’s association is driven by different genes sharing common pathways such as CTLA4 and INS, 
or HLA-DRB1 with genes others than itself, which are genes of the HLA complex genes associated 
with both T1DM and Crohn’s disease. 
The GWAS catalogue includes 59 diseases where studies have identified at least 25 associated 
genes per condition, and these were therefore used in this analysis. Using the Wilcoxon rank-sum 
test, most of these conditions did not show significant overlap of pathways derived from GWAS 
genes in the pathway space, except for a cluster of 18 disorders that strongly overlapped with each 
other (Bonferroni corrected p value < 0.05). Fourteen of these diseases were disorders commonly 
classified as diseases of immunity, while the other four were AD, age-related macular degeneration 
(ARMD), T1DM and Hypothyroidism (see Figure 2 for a segment of the data and Figure S1 for the 
full matrix). Part of this cluster is evident in Figure 2 as 11 diseases that overlap with each other in 44 
out of 55 disease-disease pairs (repeated pairs eliminated) while the full cluster of 18 disorders 
includes 127 out of 153 significant pairs as seen in Figure S1. The disorder with fewest associations 
with other diseases from the cluster was seasonal allergic rhinitis (8 out of 18), while the disorders 
out of the cluster which had highest number of associations with the cluster were atopic eczema and 
HIV-1 infection (both 2 out of 18). 
Cells 2019, 8, 425 8 of 19 
 
Figure 2. Overlap of molecular pathways in susceptibility genes for all disease. Susceptibility genes 
from association studies of multiple diseases overlap in the pathway space. Although we analyzed 59 
diseases with at least 25 susceptibility genes each, for representational purposes the figure shows 
those classified as either eye disease, immune system disease, or nervous system disease. The color of 
each square in the table represents the p value obtained when calculating whether the GWAS-genes 
of diseases A and B overlap in the pathway space more than would be expected from chance. Full 
data is presented in Figure S1. 
3.2. Among all KEGG Pathways, Associations with JAK-STAT Signaling are Shared between Diseases  
Co-Morbid with AD 
Having demonstrated that AD, together with ARMD, hypothyroidism and T1DM, share 
multiple KEGG pathways with disorders of immunity, we then explored which of these pathways 
was responsible for this overlap. In order to do this systematically, we first determined the strength 
of association of each disease with each KEGG pathway, calculating the proportion of susceptibility 
genes that a given disease has for each KEGG pathway (‘pathway load’). Then, using the US National 
Hospital Discharge Survey (NHDS), a dataset including diagnostic information from more than six 
million patients, we calculated the co-morbidity between disorders of immunity and late onset AD 
on discharge from in-patient care between 1979 and 2006. Finally, for each individual pathway we 
then calculated the degree of correlation between pathway load and comorbidity with AD. Most of 
the KEGG pathways showed no significant correlation, with only three exceptions, indicating 
possible meaningful shared pathways contributing to disease comorbidity (see Figure 3). Of these, 
‘Cytokine-cytokine interaction’(KEGG ID hsa04060) and ‘Viral myocarditis’(hsa05416) did not 
survive Bonferroni correction for multiple comparisons (uncorrected p value 0.05), while ‘JAK-
STAT’(hsa04630) did survive (uncorrected p value 0.00022) suggesting that the shared GWAS genes 
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on this pathway might contribute to the observed co-morbidity between AD and these disorders of 
immunity  
 
Figure 3. Pathways association with disease from real-world data. As described in the methods, we 
calculate the correlation between the co-incidence of the inflammatory diseases (denoted ratioAD(A)) 
and the proportion of susceptibility genes of these diseases on any given pathway (denoted 
load(A,p)).This figure shows this correlation for the three pathways where such correlation was the 
most significant. The ratioAD(A) of each disease is represented in the Y-axis, while load(A,p) is 
represented in the X-axis. Each disease is represented by a number and a color, as shown in the legend 
to the right. The p values corresponding to each pathway are, from left to right, 0.00022, 0.027 & 0.039. 
Only JAK-STAT signaling survives multiple testing correction. T1DM stands for Type 1 Diabetes 
mellitus; COPD for Chronic obstructive pulmonary disease; Cytokine-cytokine for Cytokine-cytokine 
receptor interaction pathway; JAK-STAT for JAK-STAT signaling pathway. 
3.3. Evidence for Altered JAK-STAT Pathway Gene Expression in AD Blood, Brain and in an In Vitro Model 
with Established Relevance to AD 
If the KEGG pathway is responsible for the observed co-morbidity between AD and disorders 
of immunity, then we reasoned that altered JAK-STAT signaling would be a feature of AD. In order 
to explore this, we utilised gene expression datasets from blood from human cohort studies (Datasets 
1 and 2), from brain from post-mortem human studies (Dataset 3) and from a rodent in vitro model 
relevant to AD (Dataset 4) with robust proof of concept using empirical studies with gene-
knockdown, in animal models and in post-mortem human brain.  
We first examined expression of genes from the JAK-STAT pathway (KEGG ID hsa04630) in 
blood from patients with AD compared to unaffected controls, reasoning that post-mortem brain 
might have more late-stage, secondary changes of inflammation, possibly less relevant to 
aetiopathological pathways. We used two cohorts, one a multinational longitudinal study 
(AddNeuroMed—ANM; 105 AD and 114 unaffected age matched subjects; denoted Dataset 1 in this 
manuscript), and another, a single centre longitudinal study utilising the exact same protocol 
(Dementia Case Register—DCR; 95 AD and 78 control blood samples [10]; denoted Dataset 2). In 
ANM, 15 of the 47 JAK-STAT genes measured in this dataset were significantly dysregulated when 
comparing controls with AD subjects (p < 0.05 after Bonferroni correction, see Figure 4A). A binomial 
exact test reveals that this proportion of significant genes in the JAK-STAT pathway is larger than 
expected by chance (p value 5 × 10−9). In DCR, six of the 47 JAK-STAT genes were significantly altered 
(p < 0.05), also revealing significance at the pathway level (p value 0.03). p values obtained in ANM 
were significantly correlated (p = 4 × 10−7 for Spearman correlation, see Figure 4B) with those obtained 
from DCR. We also merged both datasets and repeated the analysis, finding again 15 out of 47 genes 
were dysregulated (p < 0.05) in the AD population when compared with the control population. We 
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then examined JAK-STAT genes in the MCI population compared to unaffected controls in both 
cohort datasets, finding 10 out of 47 genes dysregulated in both studies, with binomial test being also 
significant (p value 9 × 10−5). 
A B 
Figure 4. Gene expression of JAK-STAT pathway genes in blood in AD. (A) We determined the 
expression of JAK-STAT pathway genes in blood, comparing people with AD (open circles) and MCI 
(solid circles) to unaffected individuals in the ANM/DCR study. (B): Results from datasets 1 (ANM) 
and 2 (DCR). Axis represent p values from each dataset. The solid line shows a linear regression, with 
confidence intervals in grey shading. Names are shown for the most significant genes that were also 
sampled in dataset 3. EMIF/iteration3/glmModel_comp_v1.R. 
We then examined the expression of JAK-STAT signaling genes in post-mortem brain tissue 
utilising a study of 129 AD subjects and 101 controls [11] (Dataset 3). In this cohort, 153 JAK-STAT 
genes were sampled, of which 53 showed significant dysregulation (p value < 0.05), and 37 of which 
survived multiple comparison correction (p value < 0.05 after FDR adjustment). A binomial exact test 
reveals that this proportion of significant genes in the JAK-STAT pathway is larger than expected by 
chance (p value 2 × 10−16). With respect to the five genes that were significant in ANM (Dataset 1) and 
that were also sampled in DCR (Dataset 2), TYK2 (p value 0.0002), IFNAR2 (Interferon-alpha/beta 
receptor beta chain, 0.04) and PIAS1 (E3 SUMO-protein ligase, 2 × 10−5) were also significantly altered 
in Dataset 3 (see Table 2). 
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Table 2. Comparing most significant genes. 
Gene Dataset 1 (blood, ANM) 
Dataset 2 
(blood, DCR) 
Dataset 3 
(brain, AE) 
Dataset 4 
(in-vitro) 
TYK2 5· 10−10 0.0005 0.0002 - 
PIK3R1 1· 10−6 0.03 0.3 0.5 
IFNAR2 0.0004 0.7 0.04 0.007 
AKT1 0.0003 0.001 0.5 0.001 
PIAS1 0.0007 0.0003 8· 10−5 0.016 
p values from analysis of case versus control samples when comparing RNA-expression in the 
different datasets. Among the 15 most significant genes of ANM (Dataset 1), the table shows those 
that were also sampled in DCR. (ANM-AddNeuroMed; DCR- dementia case register; AE-
ArrayExpress–see methods for details). PIK3R1 stands for Phosphatidylinositol 3-kinase regulatory 
subunit alpha; AKT1 for RAC-alpha serine/threonine-protein kinase. 
Finally, we also analyzed a previously reported [12] in vitro cell model derived dataset (Dataset 
4). This study demonstrated that in rodent neurons, exposure to Aβ induced gene expression changes 
that overlap extensively with changes in gene expression induced by the Wnt signaling antagonist, 
Dickkopf-1 (Dkk1); itself a gene induced in response to Aβ in rodent cells, animal models and human 
brain. This gene expression signature was subsequently validated in animal models with cerebral 
amyloid plaque pathology and in AD brain, as well as in a human DKK1 over-expressing mouse 
model. Knock-down of particular genes on this pathway prevented Aβ induced phenotypes 
including neurotoxicity and tau-phosphorylation. This experimental dataset contained 
measurements of 32 JAK-STAT genes, with 8 of these being significantly dysregulated (p values < 
0.05). Binomial testing showed that this proportion of dysregulated genes was higher than expected 
by chance alone (p value 0.0001). Of the four genes that were significant in ANM (Dataset 1) and were 
also sampled in all other datasets (DCR–Dataset 2, Array Express–Dataset 3; and rodent model–
Dataset 4), Akt1 (p value 0.001), Ifnar2 (0.007) and Pias1 (0.016) were also dysregulated in Dataset 4 
(see Table 2). 
3.4. Empirical Evidence for JAK-STAT Dysregulation in Both In Vitro and In Vivo Models of Aβ-Induced 
Neurotoxicity 
We then further validated these bioinformatics results using empirical studies, measuring the 
key drivers of the pathway, Jak1, Jak2, Jak3 and Tyk2, in an in vitro rat model of neuronal toxicity. 
Previously, we and many others have demonstrated that rodent neurons exposed to amyloid 
peptides are susceptible of Aβ-induced toxicity and other phenotypes, including tau phosphorylation 
and synaptic alterations [12,17–23]We therefore exposed primary neuronal cultures to 3 μM of 
oligomerised Aβ42 and real time PCR was performed at 30m, 4h and 24h after Aβ exposure (Figure 
5). Hprt1 and Actb were used as housekeeping genes for data normalization. Tyk2 showed a time-
dependent increase in expression detectable at 4h (p = 0.0077) and maintained up to 24h (p = 0.0063). 
Jak1 and Jak2 mRNA levels were only significantly increased at 24h with p values of p = 0.024 and p 
= 0.015, respectively. Jak3 expression was modulated by Aβ at any time point (p > 0.05).  
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Figure 5. The Janus kinases Jak1, Jak2 and Tyk2 are induced in vitro (rat culture) after Aβ stimulation 
in a sequential pattern. Neuronal cultures treated with 3 μM Aβ show a sequential pattern of 
induction for components of the JAK-STAT pathway. 4h after Aβ exposure Tyk2 is upregulated in rat 
primary neuronal cultures. The levels of this gene are maintained elevated 24h after Aβ incubation. 
After Tyk2 levels are induced Jak1 and Jak2 are then subsequently upregulated. 
We proceeded to test the response of the JAK-STAT pathway in an acute in vivo rat model of Aβ 
toxicity (QPS; Austria GmbH). Five male rats were subjected to bilateral intracerebroventricular 
injection of 50 μM Aβ1-42 or equal volumes of phosphate buffered saline (PBS). After 3h following 
injection, animals were sacrificed, and brains harvested for RNA extraction. We measured the mRNA 
levels for Jak1, Jak2, Jak3 and Tyk2 in entorhinal cortex from Aβ-injected rats or PBS-sham controls 
by real time PCR. 3h after Aβ injection, the levels of Jak1 (p value 0.001), Jak2 (0.0071) and Tyk3 
(0.0032) were significantly upregulated (p < 0.05) in the brains of these rats but not in control animals 
(Figure 6) providing further validation for the implication of this pathway in Aβ-mediated toxicity. 
 
Figure 6. JAK kinases are upregulated in an in vivo rat model of Aβ toxicity. Entorhinal cortex of male 
wild type rats injected with Aβ (n = 5) or with PBS (n = 5) bilaterally into the lateral ventricles was 
analyzed by real time PCR to determine the levels of Jak1, Jak2, Jak3 and Tyk2. Each sample was run 
in triplicate. Jak1, Jak2 and Tyk2 were significantly upregulated (p = 0.001, p = 0.0071, p = 0.0032 
respectively) in the Aβ-injected animals but not in the PBS injected control group. Data represented 
as normalized fold induction. Values given as mean ± s.e.m. Statistical significance determined by 
Student´s t-test. 
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4. Discussion  
We have presented here a series of integrated analyses predicated on the underlying hypothesis 
that co-morbidity of disease can, in some cases, indicate shared genetic susceptibility to disease and 
that this is manifested most robustly at the level of pathways more than at the level of single genes. 
By combining genome wide pathway association from all diseases together with their comorbidity 
with AD, we identify JAK-STAT signaling as a shared factor correlated with the degree of 
comorbidity. In the first data-driven phase utilizing gene association data we find this disease cluster 
to include a series of disorders of immunity and inflammation together with age-related macular 
degeneration (ARMD) and Type 1 Diabetes mellitus (T1DM). The association with ARMD is 
particularly interesting as it has previously been found to be a risk factor for AD [24,25], because Aβ 
is a component of the drusen pathology in the retina of people with ARMD [26,27] and because the 
gene most associated with ARMD, CFH,  encodes for a protein replicated as a biomarker of AD, 
complement factor H [28–30]. That our approach of using all GWAS data in a pathway clustering 
analysis identifies a relationship between AD and ARMD is all the more remarkable in because this 
association, in our study, is not driven by CFH. The association we find with T1DM is also intriguing 
as, although T2DM diabetes is one of the most substantiated risk factors for AD [31], our data now 
suggests that there might be a relationship also with early onset T1DM that is worth further attention.  
However, the most extensive association between shared pathways and disease we find is with 
disorders of immunity and inflammation. The role of inflammation in AD has been apparent for 
many years. This evidence is very extensive and comes from many directions [32]. It includes 
evidence the use of non-steroidal anti-inflammatory drugs appear to decrease the risk of AD [33–35], 
post-mortem studies showing that inflammation is associated with AD pathology [36,37], and in vivo 
data showing that markers of inflammation are predominant amongst protein biomarkers both in 
AD and in pre-dementia conditions [38,39]. In addition, there is increasing evidence from GWAS 
studies and from rare mutations, that genes encoding proteins involved in immunity are amongst the 
most consistently associated with disease [32]. However, when considered in isolation, the pathways 
and processes identified by AD genetic studies are predominantly those of complement signaling 
and microglial function [3,40,41]. These pathways are clearly important in diseases with very 
considerable evidence to support their role, but the approach we have used here, triangulating 
between GWAS, real-world and empirical data, and including all disease and all genes, nominates a 
pathway as part of the aetiopathogenic process that is not identified by such AD gene focused studies. 
As in any ‘big data’ approach, there are limitations both to the datasets available and to our use 
of them. First, in using the GWAS catalogue as a primary data-source, we limit ourselves to disease-
gene associations where a significant number of genes have been identified. We do this in order to 
provide sufficient power for analysis, but acknowledge that the limit of 25 susceptibility genes to 
enable a disease to enter analysis is both arbitrary and dependent on the size and numbers of studies 
that happen to have been conducted to date. Almost certainly, we miss information as a consequence 
of data limitation. Secondly, by segregating genes into pathways we attempt to overcome the intrinsic 
limitation of GWAS studies, in that biology is mechanistically enacted at the level of pathway and 
not gene, let alone SNP. Given the large number of SNPs and genes in the human genome, two 
diseases may have no elements measured in GWAS, or even sequencing studies, in common and yet 
share an overlapping disease pathogenesis. Measuring association not with SNP but with multiple 
SNPs across a gene (‘gene-wide association’) is one attempt to overcome the limitation; here we go 
one step beyond this with a pathway-wide association approach. However, in attempting to derive 
such information from the GWAS data, we are severely limited by current understanding of 
biological pathways, which is rudimentary at best. This limitation is bound to hinder our derivation 
of knowledge from information in this context. Thirdly, in seeking to identify diseases comorbid with 
AD, we have crudely utilised a dataset of concurrent diagnoses, taking no account of some of the 
confounds or other concerns of conventional epidemiology. Indeed we cannot be sure whether the 
co-morbidity we observe is due to the disease itself or the drugs used to treat the disease. However, 
we note that similar claims-level analyses of real-world clinical data have recently proven valuable 
in studying genetic and environmental factors shared amongst diseases [42] 
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We accept the limitations of our approach described above. However, in mitigation of these 
potential limitations, the datasets we examine are huge; namely, all genetic studies with all genes and 
all diseases in the first phase, and a dataset of over six million people in the second. Furthermore, we 
would suggest that some confounds are less critical in the analysis we present here. For example, in 
studies of risk and protection then clearly understanding direction of effect–whether it is the disease 
or the treatment that affects risk–is fundamental. However, it becomes less important, potentially 
irrelevant, where we are determining simply whether the same processes are involved, as both 
disease and treatment will at some level and in some cases affect the same molecular pathways, which 
are the axis of our analysis. Finally, despite the limitations of deriving knowledge from data using 
this approach, the fact that the findings replicate in observational molecular studies in man and in 
experimental studies in rodents offers strong support to the results. 
The JAK-STAT signaling pathway, nominated as a potential target for therapy through data-
driven genomics and real-world data in this study, is a key regulator of the response to mediators of 
inflammation, including cytokines, chemokines [43] and microglia activation [44]. The binding of 
cytokines (interleukin, interferon and growth factors) and other ligands (such as hormones) to their 
receptors increases tyrosine kinase activity of Janus Kinases (JAKs, including TYK2), which in turn 
phosphorylate the receptors and recruit STATs which are themselves then phosphorylated. 
Subsequent dimerization leads to nuclear translocation and transcription factor activity. Given this 
critical role in the modulation of the inflammatory response, it is not surprising that JAK-STAT 
signaling has previously been associated with inflammatory disease and targeted for therapeutics, 
some of which have been approved for clinical use [45]. The pathway has also been identified as of 
importance in relation to diabetes [46] but less often in relation to AD. Very high concentrations of 
Aβ have been shown to increase tyrosine phosphorylation and transcriptional activity in a Tyk2 
dependent manner in rodent models, and tyrosine phosphorylation of STAT3 is increased in AD 
brain [47], while inhibition of JAK-STAT3 signaling inhibits activation of astrocytes and microglia in 
animal models of neurodegeneration [48]. JAK-STAT signaling has also been identified as a 
component of plasticity, specifically long-term depression (LTD) [49,50], interesting not least because 
LTD and long term potentiation are regulated, in opposite directions, by GSK3, the predominant tau-
kinase implicated in AD pathogenesis [51–53]. 
In summary, a combined, sequential analysis of GWAS data agnostic to disease type, combined 
with real-world data of co-incidence of AD with other diseases, nominated JAK-STAT signaling 
amongst other pathways as a possible underlying pathogenetic mechanism shared across multiple 
diseases. Remarkably, these diseases–inflammatory disorders, ARMD and Diabetes had previously 
been implicated as risk factors for AD. Adding to the weight of evidence for JAK-STAT signaling in 
AD, we subsequently found altered gene expression of the pathway in multiple human and rodent 
datasets and in empirical studies of Aβ exposure in rodents, both in vitro and in vivo. These data are 
not the first to nominate JAK-STAT signaling for therapeutic intervention [54], as experiments 
suggest that humanin and colivelin protect against AD-related neurotoxicity thought its activity in 
JAK-STAT. However the combination of genetic, human and rodent, observational and empirical 
data, make a strong case to pursue this pathway as a target for therapies for AD, not least because 
clinically approved compounds already exist. This further suggests that this novel integration of 
orthogonal data is a promising approach to find novel targets in complex disorders. 
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